← Who reports today · Health Care
How Incyte (INCY) makes money: Q2 2026 revenue breakdown
US GAAP · $M · vs Q2 2025 · quarter ended 06/30/2026 · reported 07/28/2026
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. · Text: Wikipedia, CC BY-SA 4.0, abridged
More about the company
The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Key growth driver: Product royalty revenues — the fastest-growing revenue line: $175, +16% y/y. · by the Q2 2026 report
How does Incyte make money?
Incyte brought in $1.67 billion of revenue in Q2 2026, up 37.7% year over year. The largest source was Net sales: $1.49 billion, or 89% of the total, followed by Product royalty revenues ($175M, 10%) and Milestone and contract revenues ($11.2M, 0.7%). Net income for the quarter was $586 million, up 44.6% year over year.
Revenue by source, Q2 2026
- Net sales$1.49B · 89% · +40.5%
- Product royalty revenues$175M · 10% · +15.6%
- Milestone and contract revenues$11.2M · 0.7% · +124%
Shares of $1.67B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
When is INCY’s next earnings date?
Tuesday, October 27, 2026estimated
Expected around Oct 27 — based on last year’s report on Oct 28, 2025. We have not yet seen the company's announcement of the date.
How we estimate
The estimate is the date of the same-quarter report a year ago, per the company’s SEC filing, moved forward 52 weeks (same weekday). Companies usually keep the same week; the date will be replaced once INCY announces it.
Same quarter a year ago (ended September 30, 2025): revenue $1.366B, EPS (GAAP) $2.11
How we calculate
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
What time does INCY report? Usually before market open: the last 4 results releases reached the SEC at 7:02 am, 7:03 am, 7:06 am, 7:04 am ET.
Last report: Jul 28, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates: company announcements; past dates and times — SEC 8-K filings. Who else reports this week →
All figures in $M.
Revenue
$1,674
+37.7%
Operating income
$698
+31.6%
41.7% margin
Net income
$586
+44.6%
$2.81/sh · 35.0% margin
Verdict: Incyte's revenue grew 37.7% to $1.67B, operating income rose 31.6% to $697.9M and net income 44.6% to $585.6M, lifting diluted EPS to $2.81 from $2.04.
Source and notation
Source: INCY press release, 8-K EX-99.1 of 07/28/2026 (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
INCY earnings history: past report dates
| Jul 28, 2026 Tue | 7:02 ambefore market open | Jun 30, 2026 | $1.7B+38% y/y | $2.81+38% y/y |
| Apr 28, 2026 Tue | 7:03 ambefore market open | Mar 31, 2026 | $1.3B+21% y/y | $1.47+84% y/y |
| Feb 10, 2026 Tue | 7:06 ambefore market open | Dec 31, 2025 | ≈$1.5B+28% y/y | ≈$1.46+62% y/y |
| Oct 28, 2025 Tue | 7:04 ambefore market open | Sep 30, 2025 | $1.4B+20% y/y | $2.11+291% y/y |
| Jul 29, 2025 Tue | 7:06 ambefore market open | Jun 30, 2025 | $1.2B+16% y/y | $2.04 |
| Apr 29, 2025 Tue | 7:03 ambefore market open | Mar 31, 2025 | $1.1B+20% y/y | $0.80+7% y/y |
| Feb 10, 2025 Mon | 7:02 ambefore market open | Dec 31, 2024 | ≈$1.2B+16% y/y | ≈$0.90+1% y/y |
| Oct 29, 2024 Tue | 7:05 ambefore market open | Sep 30, 2024 | $1.1B+24% y/y | $0.54−29% y/y |
| Jul 30, 2024 Tue | 7:15 ambefore market open | Jun 30, 2024 | $1.0B+9% y/y | −$2.04 |
| Apr 30, 2024 Tue | 7:10 ambefore market open | Mar 31, 2024 | $881M+9% y/y | $0.75+650% y/y |
| Feb 13, 2024 Tue | 7:03 ambefore market open | Dec 31, 2023 | ≈$1.0B+9% y/y | ≈$0.89+642% y/y |
| Oct 31, 2023 Tue | 7:05 ambefore market open | Sep 30, 2023 | $919M+12% y/y | $0.76+52% y/y |
| Aug 1, 2023 Tue | 7:05 ambefore market open | Jun 30, 2023 | $955M+5% y/y | $0.90+25% y/y |
| May 2, 2023 Tue | 7:01 ambefore market open | Mar 31, 2023 | $809M+10% y/y | $0.10−41% y/y |
| Feb 7, 2023 Tue | 7:05 ambefore market open | Dec 31, 2022 | ≈$927M+7% y/y | ≈$0.12−95% y/y |
| Nov 1, 2022 Tue | 7:05 ambefore market open | Sep 30, 2022 | $823M+1% y/y | $0.50−39% y/y |
| Aug 2, 2022 Tue | 7:25 ambefore market open | Jun 30, 2022 | $911M+29% y/y | $0.72+7% y/y |
| May 3, 2022 Tue | 7:16 ambefore market open | Mar 31, 2022 | $733M+21% y/y | $0.17−29% y/y |
| Feb 8, 2022 Tue | 7:17 ambefore market open | Dec 31, 2021 | ≈$863M+9% y/y | ≈$2.54+274% y/y |
| Nov 2, 2021 Tue | 7:15 ambefore market open | Sep 30, 2021 | $813M+31% y/y | $0.82 |
| Aug 3, 2021 Tue | 7:15 ambefore market open | Jun 30, 2021 | $706M+3% y/y | $0.67−49% y/y |
| May 4, 2021 Tue | 7:08 ambefore market open | Mar 31, 2021 | $605M+6% y/y | $0.24 |
| Feb 9, 2021 Tue | 7:11 ambefore market open | Dec 31, 2020 | ≈$790M+36% y/y | ≈$0.68+33% y/y |
| Nov 5, 2020 Thu | 7:08 ambefore market open | Sep 30, 2020 | $621M+13% y/y | −$0.07 |
| Aug 4, 2020 Tue | 7:08 ambefore market open | Jun 30, 2020 | $688M+30% y/y | $1.32+175% y/y |
| May 5, 2020 Tue | 7:14 ambefore market open | Mar 31, 2020 | $569M+14% y/y | −$3.33 |
| Feb 13, 2020 Thu | 7:14 ambefore market open | Dec 31, 2019 | ≈$579M+10% y/y | ≈$0.51+59% y/y |
| Oct 29, 2019 Tue | 7:09 ambefore market open | Sep 30, 2019 | $552M+23% y/y | $0.59+321% y/y |
| Jul 30, 2019 Tue | 7:14 ambefore market open | Jun 30, 2019 | $530M+2% y/y | $0.48+100% y/y |
| Apr 30, 2019 Tue | 7:23 ambefore market open | Mar 31, 2019 | $498M+30% y/y | $0.47 |
| Feb 14, 2019 Thu | 7:16 ambefore market open | Dec 31, 2018 | ≈$528M+19% y/y | ≈$0.32 |
| Oct 30, 2018 Tue | 7:12 ambefore market open | Sep 30, 2018 | $450M+18% y/y | $0.14−18% y/y |
| Jul 31, 2018 Tue | 7:06 ambefore market open | Jun 30, 2018 | $522M+60% y/y | $0.24 |
| May 1, 2018 Tue | 7:09 ambefore market open | Mar 31, 2018 | $382M−0% y/y | −$0.19+80% y/y |
| Feb 15, 2018 Thu | 7:15 ambefore market open | Dec 31, 2017 | $444M+36% y/y | −$0.71 |
| Oct 31, 2017 Tue | 7:09 ambefore market open | Sep 30, 2017 | $382M+42% y/y | $0.17−11% y/y |
| Aug 1, 2017 Tue | 7:07 ambefore market open | Jun 30, 2017 | $326M+33% y/y | −$0.06 |
| May 4, 2017 Thu | 7:09 ambefore market open | Mar 31, 2017 | $384M+46% y/y | −$0.96 |
| Feb 14, 2017 Tue | 7:25 ambefore market open | Dec 31, 2016 | $326M+34% y/y | $0.05−83% y/y |
| Nov 1, 2016 Tue | 7:24 ambefore market open | Sep 30, 2016 | $269M+44% y/y | $0.19 |
| Aug 9, 2016 Tue | 7:12 ambefore market open | Jun 30, 2016 | $246M+51% y/y | $0.18+260% y/y |
| May 9, 2016 Mon | 10:08 amduring market hours | Mar 31, 2016 | $263M+65% y/y | $0.12 |
| Feb 11, 2016 Thu | 4:23 pmafter market close | Dec 31, 2015 | $244M+97% y/y | $0.29 |
| Nov 3, 2015 Tue | 7:30 ambefore market open | Sep 30, 2015 | $188M−5% y/y | −$0.22 |
| Aug 4, 2015 Tue | 7:27 ambefore market open | Jun 30, 2015 | $163M+64% y/y | $0.05 |
| Apr 30, 2015 Thu | 7:14 ambefore market open | Mar 31, 2015 | $159M+77% y/y | −$0.11+48% y/y |
| Feb 12, 2015 Thu | 7:26 ambefore market open | Dec 31, 2014 | $124M+28% y/y | −$0.22+21% y/y |
| Oct 30, 2014 Thu | 7:28 ambefore market open | Sep 30, 2014 | $198M+133% y/y | $0.33 |
| Jul 31, 2014 Thu | 7:20 ambefore market open | Jun 30, 2014 | $100M−2% y/y | −$0.22 |
| May 1, 2014 Thu | 7:26 ambefore market open | Mar 31, 2014 | $90M+26% y/y | −$0.21−75% y/y |
| Feb 12, 2014 Wed | 7:27 ambefore market open | Dec 31, 2013 | ≈$97M−15% y/y | ≈−$0.28 |
| Oct 31, 2013 Thu | 7:38 ambefore market open | Sep 30, 2013 | $85M+41% y/y | −$0.14+18% y/y |
| Aug 1, 2013 Thu | 7:30 ambefore market open | Jun 30, 2013 | $102M+17% y/y | −$0.02 |
| May 2, 2013 Thu | 7:28 ambefore market open | Mar 31, 2013 | $71M+96% y/y | −$0.12+67% y/y |
| Feb 14, 2013 Thu | 7:19 ambefore market open | Dec 31, 2012 | $114M+294% y/y | $0.14 |
| Nov 1, 2012 Thu | 7:42 ambefore market open | Sep 30, 2012 | $60M+260% y/y | −$0.17+60% y/y |
| Aug 2, 2012 Thu | 7:23 ambefore market open | Jun 30, 2012 | $87M+415% y/y | $0.03 |
| Apr 26, 2012 Thu | 7:28 ambefore market open | Mar 31, 2012 | $36M+13% y/y | −$0.36−71% y/y |
| Feb 15, 2012 Wed | 7:29 ambefore market open | Dec 31, 2011 | $29M | −$0.44 |
| Oct 27, 2011 Thu | 7:43 ambefore market open | Sep 30, 2011 | $17M | −$0.42 |
| Jul 28, 2011 Thu | 7:23 ambefore market open | Jun 30, 2011 | $17M | −$0.41 |
| May 3, 2011 Tue | 7:29 ambefore market open | Mar 31, 2011 | $32M | −$0.21 |
Show all 62 reports since 2011Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Incyte: 15-year financials
| 2025 | 5,141 | 1,515 | 1,287 | — |
| 2024 | 4,241 | 61.4 | 32.6 | — |
| 2023 | 3,696 | 621 | 598 | — |
| 2022 | 3,395 | 579 | 341 | 892 |
| 2021 | 2,986 | 586 | 949 | 569 |
| 2020 | 2,667 | −264 | −296 | −312 |
| 2019 | 2,159 | 402 | 447 | 633 |
| 2018 | 1,882 | 129 | 110 | 263 |
| 2017 | 1,536 | −243 | −313 | −204 |
| 2016 | 1,106 | 145 | 104 | 185 |
| 2015 | 754 | 50.7 | 6.5 | 63.4 |
| 2014 | 512 | −4.8 | −48.5 | −1.6 |
| 2013 | 355 | −16.1 | −83.1 | 4.9 |
| 2012 | 297 | 1.1 | −44.3 | −97.7 |
| 2011 | 94.5 | −143 | −187 | −166 |
Show all 15 yearsShow fewer
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Shareholders’ equity at Mar 31, 2026: $5.6B (77% of total assets). Compare with other S&P 500 companies →
Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · Piotroski F-score: S&P 500 companies scoring 8 or 9
Incyte (INCY) earnings: FAQ
How does Incyte make money?
Incyte brought in $1.67 billion of revenue in Q2 2026, up 37.7% year over year. The largest source was Net sales: $1.49 billion, or 89% of the total, followed by Product royalty revenues ($175M, 10%) and Milestone and contract revenues ($11.2M, 0.7%). Net income for the quarter was $586 million, up 44.6% year over year.
When is INCY's next earnings date?
We have not yet seen an announcement of the date from Incyte (INCY). Based on last year's report on Oct 28, 2025, the next report is expected around Oct 27, 2026.
What time does INCY report earnings?
Incyte usually reports before market open: its latest results release was filed with the SEC at 7:02 am ET on Jul 28, 2026.
When did INCY last report earnings?
Incyte reported Q2 2026 results on Jul 28, 2026.
Where can I find Incyte's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to INCY's filings; this page breaks the latest report down in a Sankey chart.
What was INCY's net income in Q2 2026?
Incyte reported net income of $586M for Q2 2026 (+44.6% year over year), under US GAAP.
How has Incyte's revenue changed since 2011?
Per its 10-K filings, revenue grew 54.4x: $95M in 2011 and $5,141M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report — two independent automated readings of the release had to match, and every number in the text was checked against it. Figures checked against the filing on 10/16/2026. How we make the breakdowns · Report an error
More reports: IQV · Q2 2026 · ISRG · Q2 2026 · JNJ · Q3 2026 · LH · Q2 2026 · LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · PFE · Q2 2026 · REGN · Q2 2026 · all reports